Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($0.61), $1.01 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $45.1 million versus the consensus estimate of $15.61 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.